In a falling month, the portfolio lost a meagre 0.6%, outperforming the benchmark S&P/ASX Small Ordinaries Accumulation Index by 2.2%.
To say the 6-month recovery from the March low has been anything but extraordinary is an understatement. The potential for a vaccine suggests that the economy could return to normal operating conditions, but the leverage and flood of liquidity in markets may not be conducive for such a return. This remains in governments hands.
We aim to achieve superior returns to the ASX Small Ordinaries Accumulation Index by investing in high growth companies. Our investment process incorporates environmental and social factors in addition to achieving our returns.